摘要

Objectives: This protocol aims to explore the use of botulinum toxin (BTX) injections and radiofrequency (RF) treatment as a combined approach to alleviate pain during intercourse (dyspareunia) in patients suffering from vulvodynia. By integrating these two treatments, we aim to enhance tissue elasticity and reduce muscular tension, improving sexual health and quality of life for affected individuals. Introduction: Vulvodynia and dyspareunia are conditions that significantly affect sexual well-being, often linked to hypertonicity in the pelvic floor muscles. Botulinum toxin, known for its ability to reduce muscle contractions by inhibiting acetylcholine release at the neuromuscular junction, has been investigated as a potential treatment for dyspareunia. The injection of BTX into the levator ani muscle, which plays a critical role in pelvic floor function, can reduce muscle spasm and alleviate pain. In parallel, radiofrequency therapy can be used in promoting tissue regeneration and vaginal elasticity. Materials / method: This protocol involves the administration of botulinum toxin directly into the levator ani muscle to address excessive muscle tension. Specifically, 100 units (UI) of botulinum toxin are injected using a fine needle across multiple points in the muscle. In combination, radiofrequency treatment is applied to the vaginal and vulvar tissues to stimulate collagen production, improve tissue elasticity, and promote healing of microtears that can occur during intercourse. The combination of muscle relaxation from BTX and the regenerative effects of RF is intended to provide a dual therapeutic benefit Results: In clinical applications, 100 UI of botulinum toxin are distributed across several injection points in the levator ani muscle, with the goal of reducing muscle hyperactivity and alleviating pain during intercourse. The radiofrequency treatment further contributes to improved tissue elasticity, which can help reduce post-coital tearing and discomfort. Our preliminary results suggest that this combined approach leads to a significant improvement in dyspareunia and overall sexual function. Conclusion: The combination of botulinum toxin injections into the levator ani and radiofrequency therapy represents a promising approach to managing vulvodynia and dyspareunia. By targeting both muscle hypertonicity and tissue elasticity, this protocol addresses the primary physical factors contributing to pain during intercourse. Further studies are necessary to validate long-term outcomes and optimize treatment protocols, but the initial results are encouraging for the improvement of sexual health and well-being.